Navigation Links
Regeneron Announces Presentation at the 2010 Deutsche Bank BioFest
Date:12/6/2010

TARRYTOWN, N.Y., Dec. 6, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 2010 Deutsche Bank BioFest on Tuesday, December 14, 2010.  The presentation is scheduled for 8:00 a.m. Eastern Time.  The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page.  An archived version of the presentation will be available after the live webcast through January 13, 2011.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com. Contact Information:Michael Aberman, M.D.

Peter DworkinInvestor Relations

Corporate Communications914.345.7799

914.345.7800michael.aberman@regeneron.com

peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Regenerons Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
2. Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
3. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
4. Sequenom Announces Exercise in Full of Underwriters Option to Purchase Additional Shares
5. The Pittsburgh Life Sciences Greenhouse Announces New Chairman of the Board
6. Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence
7. AVANIR Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Syngenta Announces Photo Prize 2010 Winners
9. 3SBio Inc. Announces Unaudited Third Quarter Results
10. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo
11. Elsevier Announces the SciVerse ScienceDirect eBooks Collection 2011 Frontlist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)... May 16, 2017 Telehealth has long ... and something that has been kept completely separate ... But according to   Logicalis Healthcare Solutions , ... IT solutions and managed services provider ( www.us.logicalis.com ... overlooked – interrelationship between telehealth, imaging, and EHR ...
(Date:5/15/2017)... Somerset, N.J. (PRWEB) , ... May 15, 2017 ... ... advanced delivery technologies and development solutions for drugs, biologics and consumer health products, ... biotechnology company focused on rare genetic diseases, to support preclinical and clinical development ...
(Date:5/12/2017)... ARBOR, Mich. , May 12, 2017 ... selected to present at the 36th annual Michigan Growth ... Forum. GreenMark, a Delaware corporation ... be presenting to investors in attendance, including more than ... deliver health benefits to society through biobased targeting technologies. ...
(Date:5/11/2017)... (PRWEB) , ... May 11, 2017 , ... ... rodent neurons both are excellent resources for disease modeling and drug screening. Human ... differentiated into mature neurons for various applications, however, these often contain mixed population ...
Breaking Biology Technology:
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
Breaking Biology News(10 mins):